**Content:**
The United States Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) have reached a $50 million settlement with retail giant Walmart, resolving allegations that its pharmacies had been filing thousands of invalid prescriptions for opioids and other controlled substances. The charges stem from a violation of the Controlled Substances Act.
Associate Attorney General Stanley Woodward emphasized the Department's commitment to protecting Americans during a press statement, highlighting the gravity of the situation. "This settlement proves this Department is committed to putting Americans' flourishing first," he said. "Congress enacted laws to promote responsibility and accountability for companies who dispense controlled substances to protect Americans. This Department will never shy away from vigorously enforcing pharmacies' obligations to comply with those protections, ensuring that potential profits never justify aiding our Nation's opioid epidemic."
The allegations against Walmart spanned over a decade, from June 26, 2013, to the present. According to the complaint, individuals within Walmart's compliance team, along with pharmacists, engaged in the illegal filing of prescriptions through "knowing actions." This included filling invalid prescriptions written by prescribers known to operate as "pill mills."
The complaint further revealed that the compliance team at Walmart, led by one director, prioritized other goals over compliance with the Controlled Substances Act. This was evidenced by a statement from the director that the compliance team viewed "driving sales and patient awareness" as "a far better use of our market directors and market manager's time."
The U.S. government also alleged that Walmart pharmacists had knowingly filed prescriptions that were invalid. These were often identified by obvious red flags, such as dangerous combinations of opioids, cocktails of opioids and non-opioids, excessively repeated fills of high-dosage opioids, or repeated requests for early fills of controlled substances.
As part of the settlement, Walmart has agreed to take several measures to address future obligations in the dispensing of controlled substances. This includes setting up a hotline for employees and patients to report suspected illegal dispensing of controlled substances. The company will also proactively monitor its pharmacies' dispensing patterns to identify and address potentially illegal dispensing. Additionally, Walmart will establish a process to evaluate prescribers suspected of illegal prescribing.
This is not the first time Walmart has faced legal scrutiny regarding the opioid crisis. In recent years, the company has been the subject of numerous lawsuits and investigations into its role in the nation's opioid epidemic. The settlement announced today is one of the largest in such cases, reflecting the severity of the allegations against Walmart.
The agreement comes as the U.S. continues to grapple with the devastating effects of the opioid crisis. The epidemic has resulted in hundreds of thousands of deaths and billions of dollars in economic costs. The Justice Department's action against Walmart is part of a broader effort to hold pharmaceutical companies accountable for their role in fueling the crisis.
Walmart's commitment to address future obligations in the dispensing of controlled substances is a significant step towards mitigating the harm caused by the illegal prescription of opioids. However, critics argue that the $50 million settlement is a drop in the bucket compared to the potential profits generated by the illegal prescriptions.
The resolution of this case will likely have implications for other pharmaceutical companies and pharmacies facing similar allegations. It underscores the need for stringent compliance with regulations aimed at preventing the misuse of opioids and other controlled substances.
In the wake of this settlement, it remains to be seen whether Walmart's actions will lead to a reduction in the illegal prescription of opioids and contribute to a reduction in the nation's opioid crisis. As the country continues to grapple with the devastating effects of the epidemic, the outcome of this case will be closely watched by advocates and policymakers alike.
(0)